ロード中...
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atheroscle...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2941781/ https://ncbi.nlm.nih.gov/pubmed/20859539 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|